Press Release
CCL Industries Announces 2024 Fourth Quarter and Record Annual Results
Fourth Quarter Highlights Per Class B share(3): $1.02 adjusted basic earnings up 5.2%; $1.01 basic earnings up 359.1%; $0.54 goodwill impairment loss in 2023 basic earnings; currency translation negative $0.01 per share Sales increased 9.0% on 6.8% organic growth, 1.4% acquisition growth and 0.8% positive currency translation CCL, Checkpoint and Innovia posted organic sales growth of 5.4%, 13.3%, and 20.2%, respectively, partly offset by an organic decline for Avery of 2.0% Operating income(1) improved 5.1%, with a 14.8% operating margin(1) down 50 bps 2024 Highlights Per Class B share(3): $4.32 adjusted basic earnings up 14.9%; $4.73 basic earnings up 58.2%; $0.44 revaluation gain included in 2024 basic earnings and $0.54 goodwill impairment loss in 2023 basic earnings; currency translation negative $0.02 per share Sales increased 9.0% on 6.1% organic growth, 2.3% acquisition growth and 0.6% positive currency translation Operating income(1) improved 13.0%, with a 15.8% operating margin(1) up 60 bps Read More
Press Release
Hispanics Critical to Meeting U.S. Projected Demand for 11.8 Million STEM Professionals by 2030, According to New Report From SHPE & LDC
SHPE and Latino Donor Collaborative released a report with key facts showcasing a 60% increase for Hispanics in AI technical roles and rising STEM degrees for Latinos that help drive the U.S. economy forward. Read More
Press Release
Catalyst Capital Markets Launches With a Focus on Micro/Small Cap and Private Issuer Capital Advisory
Founder and Chief Executive Officer is Alan Sheriff, a former Vice Chairman of PNC Bank, a founder and former Co-CEO of Solebury Capital, and former Co-Head of Equity Capital Markets, Americas, Credit Suisse First Boston Read More
Press Release
Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease Study - Short Bowel Syndrome with Intestinal Failure (SBS-IF)
This study, initiated yesterday, is one of five clinical efforts - three proof-of-concept (POC) investigator-initiated trials (IIT) and two Phase 2 studies - of crofelemer for the rare disease indications of SBS-IF and microvillus inclusion disease (MVID) in the US, EU, and/or Middle East/North Africa regions Availability of first IIT proof-of-concept results potentially in H1 2025 Crofelemer, Jaguar's novel plant-based prescription drug, has been granted Orphan-Drug Designation by the FDA and the European Medicines Agency (EMA) for both SBS-IF and MVID Read More
Press Release
DEXIS Showcases Newest Technology at Chicago Midwinter and Lab Day Conferences
The global leader in dental imaging technologies will showcase the latest innovations added to its digital ecosystem - a suite of tools and software designed to connect the entire digital workflow from diagnosis to delivery. Read More
Press Release
Tritent International Corp’s Fantribe Inc. Unveils Upcoming Launch of Game-Changing Superfan Mobile App to Revolutionize Fan Engagement and Drive Revenue Growth
New Mobile App to Offer Enhanced Features for Fans to Connect with Athletes, Celebrities, and Influencers, Opening Up New Revenue Streams for Fantribe and Tritent International Read More
Press Release
